Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA Study-authors' response

Affiliations

¹ ICONA Foundation, Milan, Italy.
² Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, ICONA Foundation, via A. di Rudinì 8, 20142, Rome, Italy.
³ Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK.

Comment

Antonella d'Arminio Monforte et al. J Antimicrob Chemother. 2023.

. 2023 Jul 5;78(7):1809-1810.

doi: 10.1093/jac/dkad152.

¹ ICONA Foundation, Milan, Italy.
² Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, ICONA Foundation, via A. di Rudinì 8, 20142, Rome, Italy.
³ Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK.

No abstract available

Comment on

Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study.
D'arminio Monforte A, Tavelli A, Sala M, Mondi A, Rusconi S, Antinori S, Puoti M, Celesia BM, Taramasso L, Saracino A, Antinori A, Cozzi-Lepri A; ICONA Foundation Study Group. D'arminio Monforte A, et al. J Antimicrob Chemother. 2023 Apr 3;78(4):933-945. doi: 10.1093/jac/dkad026. J Antimicrob Chemother. 2023. PMID: 36775983
Comment on: Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study.
Ciccullo A, Baldin G, Sterrantino G, Madeddu G, D'ettorre G, Mussini C, Di Giambenedetto S. Ciccullo A, et al. J Antimicrob Chemother. 2023 Jul 5;78(7):1808-1809. doi: 10.1093/jac/dkad151. J Antimicrob Chemother. 2023. PMID: 37220765 No abstract available.